Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges

Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges

The field of oncolytic virotherapy has seen remarkable advancements in last two decades, leading to approval of the first oncolytic immuno-virotherapy, Talimogene Laherparepvec, for the treatment of melanoma. A plethora of preclinical and clinical studies have demonstrated excellent safety profiles...

Full description

Bibliographic Details
Main Authors: Shyambabu Chaurasiya, Yuman Fong, Susanne G. Warner
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
oncolytic virus
transgene
arming
immunotherapy
Cytokines
CAR-T cells
Online Access:https://www.mdpi.com/2072-6694/12/6/1699

Internet

https://www.mdpi.com/2072-6694/12/6/1699

Similar Items